Antibody-based HIV-1 vaccines: recent developments and future directions.

Antibody-based HIV-1 vaccines: recent developments and future directions.

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Montefiori, D, Sattentau, Q, Flores, J, Esparza, J, Mascola, J
Formato:	Journal article
Lenguaje:	English
Publicado:	2007

Ejemplares similares

Antibody-based HIV-1 vaccines: recent developments and future directions
por: Montefiori, D, et al.
Publicado: (2007)

Antibody-based HIV-1 vaccines: recent developments and future directions.
por: David Montefiori, et al.
Publicado: (2007-12-01)

Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.
por: Kong, L, et al.
Publicado: (2012)

New templates for HIV-1 antibody-based vaccine design
por: Sattentau, Q, et al.
Publicado: (2010)

New templates for HIV-1 antibody-based vaccine design.
por: Sattentau, Q, et al.
Publicado: (2010)

Neutralization of HIV-1 by antibody.
por: Sattentau, Q
Publicado: (1996)

Antibody neutralization of HIV-1 and the potential for vaccine design.
por: Sattentau, Q, et al.
Publicado: (1999)

Development of prophylactic vaccines against HIV-1.
por: Schiffner, T, et al.
Publicado: (2013)

Potential role for neutralizing antibodies in HIV-1 infection
por: J. Mascola
Publicado: (2015-12-01)

Antibody neutralization of HIV-1.
por: Poignard, P, et al.
Publicado: (1996)

Idiotype vaccines for HIV based on CD4 antibodies
por: Sattentau, Q, et al.
Publicado: (1990)

IDIOTYPE VACCINES FOR HIV BASED ON CD4 ANTIBODIES
por: Sattentau, Q, et al.
Publicado: (1990)

HIV-1 antibody--debris or virion?
por: Parren, P, et al.
Publicado: (1997)

Monoclonal antibodies to HIV-1 gp120: a request.
por: Moore, J, et al.
Publicado: (1993)

HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions
por: Muni Rubens, et al.
Publicado: (2015-01-01)

HIV-Specific Antibodies Mediate Rapid Antibody-Dependent Cellular Cytotoxicity Against Primary HIV-Infected CD4+T Cells
por: Smalls-Mantey, A, et al.
Publicado: (2010)

The cat and mouse of HIV-1 antibody escape.
por: John R Mascola
Publicado: (2009-09-01)

Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies.
por: Schiffner, T, et al.
Publicado: (2013)

Correlates of antibody-mediated protection against HIV infection.
por: Sattentau, Q
Publicado: (2008)

The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
por: Parren, P, et al.
Publicado: (1999)

Fundamental immunology and what it can teach us about HIV vaccine development.
por: Mitchison, N, et al.
Publicado: (2005)

HIV-1 antibody - Debris or virion? (vol 3, pg 366, 1997)
por: Parren, P, et al.
Publicado: (1997)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: Labranche, CC, et al.
Publicado: (2018)

HIV-1-neutralizing antibody 1 induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, S, et al.
Publicado: (2017)

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
por: Medina-Ramírez, M, et al.
Publicado: (2017)

The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
por: Sheppard, N, et al.
Publicado: (2005)

Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines.
por: Clutton, G, et al.
Publicado: (2014)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, S, et al.
Publicado: (2017)

Degradable PEI Form as Safer Alternative for HIV-1 Vaccine Development and Adjuvant Potency as a Common Trait of Oligoethyleneimines
por: Brinckmann, S, et al.
Publicado: (2011)

Polyethyleneimine Is a Potent Mucosal Adjuvant and Candidate Adjuvant for HIV-1 Vaccination
por: Brinckmann, S, et al.
Publicado: (2011)

A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.
por: Moore, J, et al.
Publicado: (1992)

Limitations of the anti-idiotype strategy for an HIV vaccine.
por: Beverley, P, et al.
Publicado: (1989)

Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
por: Moore, J, et al.
Publicado: (1990)

The HIV-1-containing macrophage compartment: a perfect cellular niche?
por: Tan, J, et al.
Publicado: (2013)

Advances in Antibody-Based HIV-1 Vaccines Development
por: Ursula Dietrich
Publicado: (2020-01-01)

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
por: Dalia T. Abdeldaim, et al.
Publicado: (2023-09-01)

The role of the envelope glycoproteins in HIV-1 transmission and pathogenesis
por: Sattentau, Q
Publicado: (1996)

DNA Vaccines: Recent Developments and the Future
por: Britta Wahren, et al.
Publicado: (2014-10-01)

The Terebelliformia-Recent Developments and Future Directions
por: Pat Hutchings, et al.
Publicado: (2021-02-01)

Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4.
por: Klasse, P, et al.
Publicado: (1996)